Cannell & Co. Vertex Pharmaceuticals Inc Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
A detailed history of Cannell & Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cannell & Co. holds 1,712 shares of VRTX stock, worth $796,216. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,712
Previous 1,712
-0.0%
Holding current value
$796,216
Previous $595,000
16.97%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,707Shares Held
226MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.4 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.7 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.91 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.45 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$3.97 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $119B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...